Shingo. Nakahata, et.al., Loss of NDRG2 expression activates PI3K-AKT signalling via PTEN phosphorylation in ATLL and other cancers., Nature communications, 2014, 5

http://rdf.ncbi.nlm.nih.gov/pubmed/24569712

Shingo. Nakahata, et.al., Loss of NDRG2 expression activates PI3K-AKT signalling via PTEN phosphorylation in ATLL and other cancers., Nature communications, 2014, 5

pubmed

allele

http://purl.org/net/cito/citesAsAuthority

• Ndrg2<tm1Kmori>
  http://metadb.riken.jp/db/mgi_rdf/MGI:5617965

class

http://purl.org/net/cito/citesAsAuthority

• Ndrg2<tm1Kmori>
  http://metadb.riken.jp/db/mgi_rdf/MGI:5617965

表現型アノテーション

http://purl.org/net/cito/citesAsAuthority

• increased fibroblast proliferation_Ndrg2<tm1Kmori>/Ndrg2<tm1Kmori>
  http://metadb.riken.jp/0011703IC57BL6C57BL6NCrljCBAJNCrljNdrg2tm1KmoriNdrg2tm1KmoriNdrg2tm1Kmori
• increased pancreas tumor incidence_Ndrg2<tm1Kmori>/Ndrg2<+>
  http://metadb.riken.jp/0009153IC57BL6C57BL6NCrljCBAJNCrljNdrg2tm1KmoriNdrg2Ndrg2tm1KmoriNdrg2
• increased skin tumor incidence_Ndrg2<tm1Kmori>/Ndrg2<+>
  http://metadb.riken.jp/0010300IC57BL6C57BL6NCrljCBAJNCrljNdrg2tm1KmoriNdrg2Ndrg2tm1KmoriNdrg2
• increased brain tumor incidence_Ndrg2<tm1Kmori>/Ndrg2<+>
  http://metadb.riken.jp/0009277IC57BL6C57BL6NCrljCBAJNCrljNdrg2tm1KmoriNdrg2Ndrg2tm1KmoriNdrg2
• decreased survivor rate_Ndrg2<tm1Kmori>/Ndrg2<+>
  http://metadb.riken.jp/0008770IC57BL6C57BL6NCrljCBAJNCrljNdrg2tm1KmoriNdrg2Ndrg2tm1KmoriNdrg2
• increased tumor incidence_Ndrg2<tm1Kmori>/Ndrg2<tm1Kmori>
  http://metadb.riken.jp/0002020IC57BL6C57BL6NCrljCBAJNCrljNdrg2tm1KmoriNdrg2tm1KmoriNdrg2tm1Kmori
• increased tumor incidence_Ndrg2<tm1Kmori>/Ndrg2<+>
  http://metadb.riken.jp/0002020IC57BL6C57BL6NCrljCBAJNCrljNdrg2tm1KmoriNdrg2Ndrg2tm1KmoriNdrg2
• increased testis tumor incidence_Ndrg2<tm1Kmori>/Ndrg2<+>
  http://metadb.riken.jp/0006262IC57BL6C57BL6NCrljCBAJNCrljNdrg2tm1KmoriNdrg2Ndrg2tm1KmoriNdrg2
• increased gastrointestinal tumor incidence_Ndrg2<tm1Kmori>/Ndrg2<+>
  http://metadb.riken.jp/0010279IC57BL6C57BL6NCrljCBAJNCrljNdrg2tm1KmoriNdrg2Ndrg2tm1KmoriNdrg2
• increased lung carcinoma incidence_Ndrg2<tm1Kmori>/Ndrg2<+>
  http://metadb.riken.jp/0008714IC57BL6C57BL6NCrljCBAJNCrljNdrg2tm1KmoriNdrg2Ndrg2tm1KmoriNdrg2
• increased hepatocellular carcinoma incidence_Ndrg2<tm1Kmori>/Ndrg2<+>
  http://metadb.riken.jp/0003331IC57BL6C57BL6NCrljCBAJNCrljNdrg2tm1KmoriNdrg2Ndrg2tm1KmoriNdrg2
• increased T cell derived lymphoma incidence_Ndrg2<tm1Kmori>/Ndrg2<+>
  http://metadb.riken.jp/0002024IC57BL6C57BL6NCrljCBAJNCrljNdrg2tm1KmoriNdrg2Ndrg2tm1KmoriNdrg2
• premature death_Ndrg2<tm1Kmori>/Ndrg2<tm1Kmori>
  http://metadb.riken.jp/0002083IC57BL6C57BL6NCrljCBAJNCrljNdrg2tm1KmoriNdrg2tm1KmoriNdrg2tm1Kmori
• increased lung carcinoma incidence_Ndrg2<tm1Kmori>/Ndrg2<tm1Kmori>
  http://metadb.riken.jp/0008714IC57BL6C57BL6NCrljCBAJNCrljNdrg2tm1KmoriNdrg2tm1KmoriNdrg2tm1Kmori
• increased fibroblast proliferation_Ndrg2<tm1Kmori>/Ndrg2<+>
  http://metadb.riken.jp/0011703IC57BL6C57BL6NCrljCBAJNCrljNdrg2tm1KmoriNdrg2Ndrg2tm1KmoriNdrg2
• increased hepatocellular carcinoma incidence_Ndrg2<tm1Kmori>/Ndrg2<tm1Kmori>
  http://metadb.riken.jp/0003331IC57BL6C57BL6NCrljCBAJNCrljNdrg2tm1KmoriNdrg2tm1KmoriNdrg2tm1Kmori
• increased T cell derived lymphoma incidence_Ndrg2<tm1Kmori>/Ndrg2<tm1Kmori>
  http://metadb.riken.jp/0002024IC57BL6C57BL6NCrljCBAJNCrljNdrg2tm1KmoriNdrg2tm1KmoriNdrg2tm1Kmori
• premature death_Ndrg2<tm1Kmori>/Ndrg2<+>
  http://metadb.riken.jp/0002083IC57BL6C57BL6NCrljCBAJNCrljNdrg2tm1KmoriNdrg2Ndrg2tm1KmoriNdrg2
• decreased survivor rate_Ndrg2<tm1Kmori>/Ndrg2<tm1Kmori>
  http://metadb.riken.jp/0008770IC57BL6C57BL6NCrljCBAJNCrljNdrg2tm1KmoriNdrg2tm1KmoriNdrg2tm1Kmori